Compare Adaptive Biotechnologies Corp (ADPT) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs AngloGold Ashanti Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while AngloGold Ashanti Limited trades at $79.28 (market cap $41.50B). The key difference: AngloGold Ashanti Limited is far larger — about 12.5× Adaptive Biotechnologies Corp's market cap, and AngloGold Ashanti Limited pays a 5.6% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AU | |
|---|---|---|
Market Cap | $3.33B | $41.50B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $128.26 |
52-Week Low | $10.24 | $45.22 |
Enterprise Value | $3.19B | $40.63B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AngloGold Ashanti (AU) trades at $82.01, down 3.12% on the day, near key support at $81. The stock shows strong fundamentals with 2025 revenue surging to $9.89B and net income reaching $2.64B, driving a robust 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS, while the company announced a $1.16 dividend and a share repurchase program. Technical indicators signal bearish momentum with RSI at 80.83 suggesting overbought conditions, but analyst consensus remains bullish with a $118 price target.
Outlook is positive due to explosive revenue growth, high profitability, and shareholder returns, but risks include gold price volatility and execution challenges. The stock offers value with a P/E of 12.34, though technical weakness may pressure near-term performance. Institutional sentiment is supportive with 64% buy ratings, but investors should monitor gold market dynamics and cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
